Last reviewed · How we verify
Vaccine Support Cp (Vaccine administration)
Vaccine Support Cp (generic name: Vaccine administration) is a vaccine Biologic drug developed by Women and Infants Hospital of Rhode Island. It is currently FDA-approved for COVID-19, Influenza, Human Papillomavirus.
Vaccine Support Cp is a vaccine component that induces an immune response through biological means. It is specifically used as an anthrax vaccine absorbed, targeting the anthrax antigen.
At a glance
| Generic name | Vaccine administration |
|---|---|
| Sponsor | Women and Infants Hospital of Rhode Island |
| Drug class | vaccine |
| Target | unknown |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Approved indications
- COVID-19
- Influenza
- Human Papillomavirus
- Hepatitis A
- Hepatitis B
- Meningococcal
- Pneumococcal
- Rotavirus
- Varicella
- Measles, Mumps, and Rubella
Common side effects
Drug interactions
- Warfarin
- Aspirin
- Ibuprofen
- Acetaminophen
- Corticosteroids
- Immunosuppressants
- Live attenuated vaccines
- Interferons
- Thalidomide
- Azathioprine
Key clinical trials
- DNA Vaccine Therapy in Treating Patients With Chronic Hepatitis C Virus Infection (PHASE1)
- Safety Evaluation of PfSPZ Vaccine in Pregnant Women in Mali (MalVIP1) (PHASE1)
- HER2 Directed Dendritic Cell Vaccine During Neoadjuvant Therapy of HER2+Breast Cancer (EARLY_PHASE1)
- Recombinant Zoster Vaccine in Young Adult Solid Organ Transplant Recipients (PHASE4)
- A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplant (PHASE1)
- Evaluation of a Cancer Lysate Vaccine and Montanide (Registered Trademark) ISA-51 VG With or Without the IL-15 Super-Agonist N-803 as Adjuvant Therapy for PD-L1 Negative Non-Small Cell Lung Cancer (PHASE1, PHASE2)
- Testing the SurVaxM Vaccine for Lung Cancer Prevention (PHASE2)
- IGFBP-2 Vaccine to Prevent Ovarian Cancer Progression in Patients With Serologic Detection of Recurrence (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Vaccine Support Cp CI brief — competitive landscape report
- Vaccine Support Cp updates RSS · CI watch RSS
- Women and Infants Hospital of Rhode Island portfolio CI
Frequently asked questions about Vaccine Support Cp
What is Vaccine Support Cp?
What is Vaccine Support Cp used for?
Who makes Vaccine Support Cp?
What is the generic name of Vaccine Support Cp?
What drug class is Vaccine Support Cp in?
What development phase is Vaccine Support Cp in?
What does Vaccine Support Cp target?
Related
- Drug class: All vaccine drugs
- Target: All drugs targeting unknown
- Manufacturer: Women and Infants Hospital of Rhode Island — full pipeline
- Therapeutic area: All drugs in Immunology
- Indication: Drugs for COVID-19
- Indication: Drugs for Influenza
- Indication: Drugs for Human Papillomavirus
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing